GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » EV-to-EBIT

Shire (SHPG) EV-to-EBIT : 16.64 (As of Apr. 26, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Shire EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Shire's Enterprise Value is $54,842 Mil. Shire's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 was $3,296 Mil. Therefore, Shire's EV-to-EBIT for today is 16.64.

The historical rank and industry rank for Shire's EV-to-EBIT or its related term are showing as below:

SHPG's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 8.41
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Shire's Enterprise Value for the quarter that ended in Sep. 2018 was $70,423 Mil. Shire's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 was $3,296 Mil. Shire's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2018 was 4.68%.


Shire EV-to-EBIT Historical Data

The historical data trend for Shire's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire EV-to-EBIT Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.14 12.04 30.52 83.67 26.32

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.02 26.32 22.82 22.39 21.89

Competitive Comparison of Shire's EV-to-EBIT

For the Biotechnology subindustry, Shire's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shire's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shire's EV-to-EBIT falls into.



Shire EV-to-EBIT Calculation

Shire's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=54842.370/3296.1
=16.64

Shire's current Enterprise Value is $54,842 Mil.
Shire's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,296 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shire  (NAS:SHPG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Shire's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2018 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2018 ) =EBIT / Enterprise Value (Q: Sep. 2018 )
=3296.1/70423.08554
=4.68 %

Shire's Enterprise Value for the quarter that ended in Sep. 2018 was $70,423 Mil.
Shire's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,296 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shire EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Shire's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPG) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085